Understanding Dexrazoxane (CAS 24584-09-6): A Key Pharmaceutical Intermediate
In the complex world of pharmaceutical development, certain chemical compounds stand out for their critical roles as intermediates. Dexrazoxane, identified by its CAS number 24584-09-6, is one such compound. Its significance lies not only in its chemical properties but also in its vital application in medicine, particularly in mitigating the harsh side effects of cancer treatments.
As a key pharmaceutical intermediate, Dexrazoxane (C11H16N4O4, MW 268.27) is widely sought after by researchers and manufacturers. Its primary application is as a cardioprotective agent, specifically designed to counteract the damaging effects of anthracycline drugs used in chemotherapy. By chelating iron ions, Dexrazoxane prevents the formation of free radicals that can lead to cardiac damage, thereby preserving heart function in patients undergoing treatment. This crucial supportive role underscores its importance in modern oncology.
For those involved in drug discovery and development, understanding the properties of Dexrazoxane is essential. Its physical form is typically a white to off-white powder, and its handling requires adherence to safety guidelines, as indicated by its hazard statements (e.g., H315, H319, H335) and precautionary statements. We, as a dedicated supplier in China, ensure that our Dexrazoxane meets high purity standards, making it suitable for advanced pharmaceutical research and manufacturing.
Purchasing Dexrazoxane involves choosing a reliable supplier who can guarantee consistent quality and timely delivery. Whether for laboratory research or larger-scale synthesis, securing a stable supply of this intermediate is critical. We actively support the pharmaceutical industry by offering Dexrazoxane that adheres to strict quality controls, aiding in the development of safer and more effective treatments. Exploring the applications of this CAS 24584-09-6 compound further highlights its indispensable nature in pharmaceutical chemistry.
As a key pharmaceutical intermediate, Dexrazoxane (C11H16N4O4, MW 268.27) is widely sought after by researchers and manufacturers. Its primary application is as a cardioprotective agent, specifically designed to counteract the damaging effects of anthracycline drugs used in chemotherapy. By chelating iron ions, Dexrazoxane prevents the formation of free radicals that can lead to cardiac damage, thereby preserving heart function in patients undergoing treatment. This crucial supportive role underscores its importance in modern oncology.
For those involved in drug discovery and development, understanding the properties of Dexrazoxane is essential. Its physical form is typically a white to off-white powder, and its handling requires adherence to safety guidelines, as indicated by its hazard statements (e.g., H315, H319, H335) and precautionary statements. We, as a dedicated supplier in China, ensure that our Dexrazoxane meets high purity standards, making it suitable for advanced pharmaceutical research and manufacturing.
Purchasing Dexrazoxane involves choosing a reliable supplier who can guarantee consistent quality and timely delivery. Whether for laboratory research or larger-scale synthesis, securing a stable supply of this intermediate is critical. We actively support the pharmaceutical industry by offering Dexrazoxane that adheres to strict quality controls, aiding in the development of safer and more effective treatments. Exploring the applications of this CAS 24584-09-6 compound further highlights its indispensable nature in pharmaceutical chemistry.
Perspectives & Insights
Future Origin 2025
“In the complex world of pharmaceutical development, certain chemical compounds stand out for their critical roles as intermediates.”
Core Analyst 01
“Its significance lies not only in its chemical properties but also in its vital application in medicine, particularly in mitigating the harsh side effects of cancer treatments.”
Silicon Seeker One
“Its primary application is as a cardioprotective agent, specifically designed to counteract the damaging effects of anthracycline drugs used in chemotherapy.”